Hélène Peyro-Saint-Paul
Chief Tech/Sci/R&D Officer bei QIAGEN MARSEILLE
Profil
Hélène Peyro-Saint-Paul is currently the Chief Medical Officer at QIAGEN Marseille SA since 2009.
Prior to this, she worked as the Chief Medical Officer at MedDay Pharmaceuticals SAS.
She holds a doctorate degree from Université Fédérale Toulouse Midi-Pyrénées, undergraduate and graduate degrees from Université Pierre et Marie Curie, and an MBA from ESSEC Business School, which she received in 2000.
Aktive Positionen von Hélène Peyro-Saint-Paul
| Unternehmen | Position | Beginn |
|---|---|---|
| QIAGEN MARSEILLE | Chief Tech/Sci/R&D Officer | 26.01.2009 |
Ehemalige bekannte Positionen von Hélène Peyro-Saint-Paul
| Unternehmen | Position | Ende |
|---|---|---|
MedDay Pharmaceuticals SAS
 MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Hélène Peyro-Saint-Paul
| Université Fédérale Toulouse Midi-Pyrénées | Doctorate Degree |
| ESSEC Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
| Université Pierre et Marie Curie | Consumer Services |
QIAGEN Marseille SA
 QIAGEN Marseille SA Miscellaneous Commercial ServicesCommercial Services QIAGEN Marseille SA is a molecular diagnosis company, which focuses on the development and marketing of diagnostic tests in the field of oncology. Its products are used for diagnosis, prognosis and monitoring of patients with leukemia. The company was founded by Vincent Fert, Stéphane Debono, and Fabienne Hermitte on September 23, 1999 and is headquartered in Marseille, France. | Commercial Services |
MedDay Pharmaceuticals SAS
MedDay Pharmaceuticals SAS BiotechnologyHealth Technology MedDay Pharmaceuticals SAS operates as a biotechnology company developing new drugs for nervous system disorders. The firm operates for the treatment of neuro-metabolic diseases. The company was founded by Frédéric Sedel and Guillaume Brion in 2011 and is headquartered in Paris, France. | Health Technology |
